- Direction
- Unknown
- Own history
- —
- Peers
- 89th
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTBridgeBio Pharma, Inc.'s latest supported as-filed period reports revenue of $353.2M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 744.70% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.08% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -12.51% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 192.60% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 16.91% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 94.21% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 192.6%; Operating margin moved 11700 bp higher; Operating income increased 92.0%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 138.5%; Operating cash flow increased 59.7%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 120.4%; Operating margin moved 7750 bp higher; Operating income increased 20.3%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Inventory increased 189.1%; Inventory / revenue moved 515 bp higher.
2 evidence-backed componentsCurrent assets changed +143.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BBIO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001743881-26-000034SEC ↗8-KOct 29, 2026Period Oct 29, 20260001743881-26-000033SEC ↗8-KOct 13, 2026Period Oct 6, 20260001140361-26-039334SEC ↗4Sep 21, 2026Period Sep 17, 20260001470831-26-000897SEC ↗8-KAug 31, 2026Period Aug 31, 20260001140361-26-035055SEC ↗4Aug 20, 2026Period Aug 18, 20260001470831-26-000848SEC ↗4Aug 18, 2026Period Aug 16, 20260001470831-26-000837SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 17, 2026Filed Sep 21, 2026 | Kumar NeilChief Executive Officer | Open Market SaleIndirect | 8,721 | $69 | $601,868 | Form 4 ↗ |
| Sep 17, 2026Filed Sep 21, 2026 | Kumar NeilChief Executive Officer | Open Market SaleIndirect | 1,279 | $70 | $88,980 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 20, 2026 | Kumar NeilChief Executive Officer | Open Market SaleIndirect | 8,100 | $84 | $679,256 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 20, 2026 | Kumar NeilChief Executive Officer | Open Market SaleIndirect | 1,800 | $85 | $152,436 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.operating_margin
Raw value -3.30% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 40.63% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 11.29% · OPTIONAL
Total assets changed +116.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed -72.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed -76.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -5154 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed +59.6% from the comparable as-filed period.
Operating income changed +92.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001470831-26-000836| Aug 19, 2026Filed Aug 20, 2026 |
| Kumar NeilChief Executive Officer |
| Open Market SaleIndirect |
| 100 |
| $86 |
| $8,565 |
| Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Kumar NeilChief Executive Officer | Open Market SaleDirect | 1,900 | $81 | $154,184 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Kumar NeilChief Executive Officer | Open Market SaleDirect | 17,279 | $82 | $1.4M | Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Kumar NeilChief Executive Officer | Open Market SaleDirect | 14,602 | $83 | $1.2M | Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Kumar NeilChief Executive Officer | Open Market SaleDirect | 1,199 | $84 | $100,444 | Form 4 ↗ |